STOCKHOLM, Feb. 20, 2025 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that BioArctic and its partner Bristol Myers Squibb (NYSE: BMY) have received clearance from the U.S. Federal Trade Commission (FTC) for BioArctic to out-license its...
Hence then, the article about bioarctic s global license agreement with bristol myers squibb for pyroglutamate amyloid beta antibody program effective after antitrust clearance and closing was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( BioArctic's global license agreement with Bristol Myers Squibb for PyroGlutamate-amyloid-beta antibody program effective after antitrust clearance and closing )
Also on site :
- This Landmark Was Just Ranked ‘Most Loved in the World’—and It's Not the Eiffel Tower
- Kremlin responds to ‘borderline crazy’ threat from NATO state
- This Savory New $5 Sam’s Club Snack Puts the Dip in the Chip